Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Johannes CB, Caro JJ, Hartz SC, Marrs R. Adverse effects of ovulatory stimulants: a review. Assist Reprod Rev. 1993;3:68-74.